A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer

a study on Breast Cancer

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at UCLA UCSD UCSF
Dates
study started
study ends around
Principal Investigator
by Aditya Bardia, MD, MPH (ucla)
Headshot of Aditya Bardia
Aditya Bardia

Description

Summary

This is a first-in-human study of MEN2312, a lysine acetyltransferase 6 (KAT6) inhibitor, in adult participants with advanced breast cancer.

Official Title

A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer

Keywords

Advanced Breast Cancer, First-In-Human, MEN2312, KAT6, elacestrant, MEN2312: Monotherapy

Eligibility

You can join if…

Open to people ages 18 years and up

  • Participants with advanced breast cancer that cannot be cured.
  • Participant must have received at least one prior line of endocrine therapy for advanced/metastatic disease. Progression on previous cyclin-dependent kinase 4/6 inhibitor treatment in combination with fulvestrant or aromatase inhibitor is required.
  • Up to 6 prior lines of therapy are allowed. Up to 2 prior chemotherapy and/or cytotoxic antibody-drug conjugates regimens in the advanced/metastatic setting is permitted.

You CAN'T join if...

  • New or active brain metastasis.
  • Severe internal organ spread that could cause immediate life-threatening problems, including large uncontrolled fluid build-up or severe lung or liver involvement.

Note: Other inclusion/exclusion criteria may apply.

Locations

  • UC San Diego Moores Cancer Center accepting new patients
    La Jolla 5363943 California 5332921 92093-0698 United States
  • Helen Diller Family Comprehensive Cancer Center not yet accepting patients
    San Francisco 5391959 California 5332921 94115 United States
  • UCLA Hematology Oncology - Parkside accepting new patients
    Santa Monica 5393212 California 5332921 90404 United States
  • City of Hope Medical Center not yet accepting patients
    San Francisco 5391959 California 5332921 91010 United States

Lead Scientist at University of California Health

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Stemline Therapeutics, Inc.
ID
NCT06638307
Phase
Phase 1 Breast Cancer Research Study
Study Type
Interventional
Participants
Expecting 124 study participants
Last Updated